Drug intelligence / Profile preview

rDEN3-3'D4delta30

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

rDEN3-3'D4delta30 is a live-attenuated dengue virus vaccine candidate specifically targeting serotype 3 (DENV-3). Developed by the National Institute of Allergy and Infectious Diseases (NIAID), it was designed to overcome the insufficient attenuation observed in earlier DENV-3 candidates (such as rDEN3delta30). The vaccine is a chimeric virus consisting of the wild-type DENV-3 (strain Sleman/78) genetic background, but with its 3' untranslated region (UTR) replaced by the 3' UTR of the attenuated rDEN4delta30 vaccine candidate. This modification incorporates a 30-nucleotide deletion (delta30) that provides the necessary attenuation while maintaining immunogenicity. It has been evaluated in Phase 1 clinical trials as a monovalent vaccine and serves as the DENV-3 component in the tetravalent dengue vaccine formulations TV003 and TV005.

Other names: rDEN3-3'D4delta30rDEN3-3'Ddelta30Dengue virus type 3 vaccine candidate

Beyond the preview

Go deeper on rDEN3-3'D4delta30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rDEN3-3'D4delta30.

Explore the full profile